Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 01 Jun 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Psoriasis
- Focus Registrational; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 24 May 2017 Status changed from recruiting to active, no longer recruiting.
- 03 Oct 2016 Status changed from not yet recruiting to recruiting.
- 29 Sep 2016 New source identified and integrated (European Clinical Trials Database; EudraCT2016-000613-79)